Mirum Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-23.4M | $-87.9M | $-163.4M | $-135.7M | $-84.0M | $-103.3M | $-52.6M |
| Depreciation & Amortization | $24.2M | $23.6M | $10.8M | $3.2M | $595.0K | $305.0K | $139.0K |
| Depreciation | — | — | — | — | — | — | — |
| Amortization | $23.9M | $23.1M | $10.5M | $2.9M | $300.0K | — | — |
| Stock-Based Compensation | $71.4M | $48.4M | $35.0M | $27.0M | $23.1M | $12.6M | $6.1M |
| Net Cash from Operating Activities | $55.8M | $10.3M | $-70.9M | $-120.1M | $-132.8M | $-89.1M | $-39.4M |
| Investing Activities | |||||||
| Capital Expenditures | $954.0K | $993.0K | $109.0K | $278.0K | $24.0K | $225.0K | $281.0K |
| Business Acquisitions | $0 | $0 | $212.8M | $0 | $0 | — | — |
| Net Cash from Investing Activities | $-24.0M | $-90.1M | $-107.2M | $7.7M | $48.5M | $37.9M | $-127.8M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $40.1M | $17.7M | $336.6M | $109.1M | $73.5M | $181.3M | $127.2M |
| Net Change in Cash | $75.2M | $-63.4M | $158.3M | $-3.3M | $-10.7M | $130.1M | $-40.0M |
| Free Cash Flow | $54.9M | $9.3M | $-71.1M | $-120.4M | $-132.8M | $-89.3M | $-39.6M |